C1 esterase refers to the activated enzymes in the C1 complex, a group of proteins that kick-starts one of your body’s key immune defense systems. In everyday medical conversations, though, the term almost always points to C1 esterase inhibitor (C1-INH), the protein that keeps those enzymes in check. When C1-INH is missing or not working properly, the result can be dangerous episodes of tissue swelling known as hereditary angioedema. Understanding what C1 esterase does, and what happens when it’s out of balance, is central to diagnosing and managing that condition.
The C1 Complex and the Classical Complement Pathway
Your immune system has a set of proteins called the complement system that helps destroy bacteria, clear damaged cells, and trigger inflammation. The classical complement pathway is one branch of this system, and it begins with a structure called the C1 complex. This complex is made up of three proteins: C1q, C1r, and C1s.
When C1q recognizes a target, such as an antibody attached to a pathogen, the two partner proteins C1r and C1s activate and begin cutting other complement proteins (C4 and C2) into smaller pieces. Those fragments assemble into new enzymes that continue the cascade, ultimately punching holes in invading cells or flagging them for destruction. C1r and C1s are the “esterase” enzymes in this process, which is where the name C1 esterase comes from.
What C1 Esterase Inhibitor Does
C1 esterase inhibitor is the protein responsible for putting the brakes on C1r and C1s before they cause too much inflammation. It belongs to a family of proteins called serpins, which work as “suicide substrates.” C1-INH essentially tricks the target enzyme into binding to it, then locks the enzyme in a permanent grip that neutralizes it. The specific point where C1-INH snags its target is a bond between two amino acids (arginine-444 and threonine-445) on a loop of the inhibitor that mimics the enzyme’s normal substrate.
But C1-INH does far more than just police the complement system. It is the primary regulator of the kallikrein-kinin system, a separate cascade that controls blood vessel dilation and permeability. It also helps regulate parts of the clotting and clot-dissolving (fibrinolysis) pathways. In the kallikrein-kinin system specifically, C1-INH inhibits two key enzymes, activated factor XII and plasma kallikrein, preventing them from amplifying each other in a feedback loop. By doing so, it keeps production of a small peptide called bradykinin within a normal range. Bradykinin is the molecule that tells blood vessels to relax and become more permeable, functions that are essential in small amounts but dangerous in excess.
What Happens When C1-INH Is Deficient
When C1-INH activity drops to roughly 5% to 30% of normal, the kallikrein-kinin system runs unchecked. Factor XII and plasma kallikrein activate each other in an escalating cycle, generating far too much bradykinin. The excess bradykinin forces blood vessels to dilate and leak fluid into surrounding tissues, producing episodes of deep, often painful swelling. This is the core mechanism behind hereditary angioedema (HAE).
Swelling episodes in HAE typically affect the hands, feet, face, airway, and gastrointestinal tract. Abdominal attacks can mimic surgical emergencies, and throat swelling can become life-threatening if it blocks the airway. Unlike allergic swelling, HAE episodes don’t respond to antihistamines or epinephrine because the problem isn’t histamine. It’s bradykinin.
Types of Hereditary Angioedema
HAE caused by problems with C1-INH falls into two categories. Type I, the more common form, occurs when the body simply doesn’t produce enough C1-INH protein. Blood tests show low total levels of the protein. Type II occurs when the body produces normal or even elevated amounts of C1-INH, but the protein itself is structurally abnormal and doesn’t function correctly. In Type II, the total protein level may look fine on a standard test, but a functional activity assay will reveal the deficiency.
There is also a third category, sometimes called HAE with normal C1-INH, in which patients experience the same kind of swelling episodes but their C1-INH levels and function both test within normal ranges. This form involves different genetic mutations and is harder to diagnose.
Acquired C1-INH Deficiency
Not all C1-INH deficiency is inherited. Acquired C1 esterase inhibitor deficiency is a rare condition that develops later in life, typically in association with autoimmune diseases or low-grade cancers of certain white blood cells (B-cell lymphoproliferative disorders). In these cases, the body either consumes C1-INH faster than it can be made or produces antibodies that neutralize it. The swelling episodes look clinically identical to hereditary forms, but the onset in middle age or later, without a family history, points toward an acquired cause.
How C1-INH Deficiency Is Diagnosed
Diagnosis typically starts with a blood test for complement component C4. Almost all patients with C1-INH-related HAE have persistently low C4 levels because the uncontrolled C1 enzymes chew through C4 faster than the body replaces it. Low C4 is a useful and widely available screening tool, but it isn’t perfect. A small number of patients show normal C4 between attacks, and treatment with certain hormonal medications can push C4 levels back toward normal. Research has found that measuring how much of the C4 in blood has already been broken down (the ratio of cleaved C4 to total C4) is more reliable than measuring total C4 alone.
If screening raises suspicion, the next step is measuring C1-INH directly. A standard antigenic test measures how much C1-INH protein is present (normal range roughly 19 to 37 mg/dL), while a functional assay measures how well it works (normal is above 67% activity). Checking both values is important: Type I HAE shows low on both tests, while Type II shows normal or high protein but low function. Normal reference ranges for C4 fall between 10 and 49 mg/dL, and for C1q between 12 and 22 mg/dL.
Treatment Options
Treatment for C1-INH deficiency focuses on two goals: stopping acute swelling episodes and preventing them from happening in the first place. For acute attacks, both plasma-derived and lab-made (recombinant) forms of C1-INH can be infused intravenously, with symptom relief typically beginning within 30 minutes to a few hours.
For long-term prevention, C1-INH replacement is available in both intravenous and subcutaneous formulations. The subcutaneous version can be self-administered at home, which has significantly improved quality of life for many patients. International guidelines from the World Allergy Organization and the European Academy of Allergy and Clinical Immunology recommend that all HAE patients have access to on-demand treatment and that those with frequent or severe attacks receive routine prophylaxis. Special considerations apply to children and to women who are pregnant or breastfeeding, as some therapies are not appropriate for every patient group.
Patients are also encouraged to track their attack frequency, severity, and overall disease impact over time. Monitoring helps guide decisions about whether to start, adjust, or change preventive therapy.